Placebo-controlled, double-blind, parallel group, fixed dose study of KW-6002 (istradefylline) in the treatment of Parkinson's disease (phase 2 study)

Trial Profile

Placebo-controlled, double-blind, parallel group, fixed dose study of KW-6002 (istradefylline) in the treatment of Parkinson's disease (phase 2 study)

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Istradefylline (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2017 Kyowa Hakko Kirin Co., Ltd formed in Oct 2008,and study has been completed in Aug 2008,hence not added in association
    • 13 Apr 2010 Primary endpoint 'Off time' has been met, according to an article published in Movement Disorders.
    • 07 Jun 2009 Results presented at the 13th International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top